Rhythm Pharmaceuticals, Inc.

( )
RYTM After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -3.76%167.520.0%$1577.49m
NVAXNovavax, Inc. -2.13%90.3678.2%$619.81m
AMGNAmgen, Inc. -1.04%228.901.4%$514.94m
BIIBBiogen, Inc. -2.12%225.911.8%$488.90m
GILDGilead Sciences, Inc. -1.82%67.811.0%$457.29m
BNTXBioNTech SE -3.17%156.530.0%$424.65m
REGNRegeneron Pharmaceuticals, Inc. -0.60%614.382.7%$390.30m
ILMNIllumina, Inc. -1.02%380.443.3%$382.15m
VRTXVertex Pharmaceuticals, Inc. -0.97%228.611.9%$331.12m
SNSSSunesis Pharmaceuticals, Inc. -4.17%2.760.7%$192.93m
EXASEXACT Sciences Corp. -0.13%76.0317.9%$160.43m
ARNAArena Pharmaceuticals, Inc. -0.55%91.0113.7%$137.96m
ALNYAlnylam Pharmaceuticals, Inc. -0.22%138.318.2%$131.22m
INCYIncyte Corp. -0.03%74.762.4%$129.57m
BMRNBioMarin Pharmaceutical, Inc. -1.80%84.454.2%$102.33m

Company Profile

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. The firm focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.